Known targets — ChEMBL curated mechanism
CSF1RFGFR1FGFR3FLT1FLT4ITKKDRKITLCKPDGFRAPDGFRB
The experimentally established mechanism targets of Pazopanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 15/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 10/20 | 0.98 |
| ▸ | PDGFRA known ✓ | P16234 | 9/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.98 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.98 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | AURKA | O14965 | 1/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pazopanib SCHEMBL29386934 | 1.00 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL935692 | 0.99 | KDR (0.97) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL588608 | 0.99 | KDR (1.00) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL29392503 | 0.99 | KDR (1.00) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL29520402 | 0.98 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL3173301 | 0.97 | KDR (0.95) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025440 | 0.94 | KDR (0.90) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025438 | 0.94 | KDR (0.90) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025441 | 0.93 | KDR (0.89) | KDRKITPDGFRAFLT1FLT4 | |
| SCHEMBL22720091 | 0.93 | KDR (0.89) | KDRKITPDGFRAFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4628 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124153-A1 | METAL OXIDE ENCAPSULATED DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAME | APPLIED MATERIALS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4719365-A1 | COMBINATION THERAPY WITH A MTOR INHIBITOR AND A MULTI-TYROSINE KINASE INHIBITOR FOR TREATING SOFT TISSUE SARCOMA | Aadi Bioscience, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| US-20260042816-A1 | TYROSINE KINASE INHIBITOR AND ACTIVIN TYPE 2 RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATING PULMONARY ARTERIAL HYPERTENSION (PAH) | GB002 INC (US) | 2026-02-12 | — | — | US | claimed |
| EP-4662203-A1 | BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS | Translatum Medicus Inc. (CA) | 2025-12-17 | — | — | EP | claimed |
| US-12478683-B2 | Brush prodrugs and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-11-25 | — | — | US | claimed |
| EP-3957329-B1 | COMPOSITION COMPRISING THE COMBINATION OF SOTAGLIFLOZIN AS THE SODIUM/GLUCOSE CO-TRANSPORTER 1 INHIBITOR (SGLT1) AND A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 INHIBITOR (VEGFR2) FOR USE IN TREATING CANCER | NEWISH TECH BEIJING CO LTD (CN) | 2025-11-19 | — | — | EP | claimed |
| EP-4637769-A1 | METHODS OF TREATING ADVANCED SOLID TUMORS | Kura Oncology, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4630456-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | Mythic Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2014066204-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2014-05-01 | — | — | WO | claimed |
| US-20130237554-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2013-09-12 | — | — | US | claimed |
| EP-2608790-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| US-20130165456-A1 | COMBINATION | NOVARTIS AG (CH) | 2013-06-27 | — | — | US | claimed |
| WO-2013066616-A1 | PAZOPANIB FORMULATION | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2013-05-10 | — | — | WO | claimed |
| EP-2575460-A1 | COMBINATION | GlaxoSmithKline LLC (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2012027438-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2012-03-01 | — | — | WO | claimed |
| US-8114885-B2 | Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer | GLAXOSMITHKLINE LLC (US) | 2012-02-14 | — | — | US | claimed |
| WO-2011150044-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-12-01 | — | — | WO | claimed |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-12-20 | — | — | US | claimed |